- Home
- SKYE vs BVFL Comparison
SKYE vs BVFL Comparison
Compare SKYE & BVFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYE
- BVFL
- Stock Information
- Founded
- SKYE 2012
- BVFL 1873
- Country
- SKYE United States
- BVFL United States
- Employees
- SKYE N/A
- BVFL N/A
- Industry
- SKYE Biotechnology: Pharmaceutical Preparations
- BVFL Savings Institutions
- Sector
- SKYE Health Care
- BVFL Finance
- Exchange
- SKYE Nasdaq
- BVFL Nasdaq
- Market Cap
- SKYE 172.9M
- BVFL 162.8M
- IPO Year
- SKYE N/A
- BVFL N/A
- Fundamental
- Price
- SKYE $6.35
- BVFL $14.36
- Analyst Decision
- SKYE Strong Buy
- BVFL
- Analyst Count
- SKYE 4
- BVFL 0
- Target Price
- SKYE $19.25
- BVFL N/A
- AVG Volume (30 Days)
- SKYE 156.3K
- BVFL 12.9K
- Earning Date
- SKYE 08-09-2024
- BVFL 10-23-2024
- Dividend Yield
- SKYE N/A
- BVFL N/A
- EPS Growth
- SKYE N/A
- BVFL 44.67
- EPS
- SKYE N/A
- BVFL 1.41
- Revenue
- SKYE N/A
- BVFL $37,406,000.00
- Revenue This Year
- SKYE N/A
- BVFL N/A
- Revenue Next Year
- SKYE N/A
- BVFL N/A
- P/E Ratio
- SKYE N/A
- BVFL $10.07
- Revenue Growth
- SKYE N/A
- BVFL 3.92
- 52 Week Low
- SKYE $1.44
- BVFL $9.86
- 52 Week High
- SKYE $19.41
- BVFL $15.00
- Technical
- Relative Strength Index (RSI)
- SKYE 55.48
- BVFL 66.54
- Support Level
- SKYE $5.71
- BVFL $14.17
- Resistance Level
- SKYE $6.69
- BVFL $14.37
- Average True Range (ATR)
- SKYE 0.71
- BVFL 0.21
- MACD
- SKYE 0.11
- BVFL -0.03
- Stochastic Oscillator
- SKYE 59.12
- BVFL 72.55
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About BVFL BV Financial Inc.
BV Financial Inc is a federally-chartered savings and loan holding company engaged in offering traditional financial services to consumers and businesses. It offers savings, interest checking, money market, personal and business checking, non-interest checking, education savings, small business checking, business checking as well as certificates of deposit and IRA certificates of deposit. The Company's sources of revenue are derived from interest and dividends earned on loans and investment securities.